Literature DB >> 7871558

Retrievable, replaceable, macroencapsulated pancreatic islet xenografts. Long-term engraftment without immunosuppression.

K Jain1, H Yang, B R Cai, B Haque, A I Hurvitz, C Diehl, T Miyata, B H Smith, K Stenzel, M Suthanthiran.   

Abstract

Prevention of rejection and prolongation of graft survival are critical to achieving successful islet cell transplantation. Various techniques have been utilized to prolong graft survival. Recently, protection of pancreatic islets from host immune mechanisms by isolating the islets in artificial membranes has emerged as an attractive alternative to the use of immunosuppression. In this Rapid Communication, we describe a novel method for macroencapsulation of rat islets in hydrophilic macrobeads made with various combinations of agarose, collagen, and Gelfoam. Encapsulated xenotypic islets were placed intraperitoneally in mice in which diabetes was induced by streptozotocin. The encapsulated xenografts maintained normoglycemia > 170 days. Recipients mice had normal glucose tolerance tests, which indicates that the islets in the macrobeads were functioning as they would in an intact pancreas. Macrobeads retrieved up to 103 days after transplantation showed no evidence of tissue reaction or local inflammation. These retrieved macrobeads could also be retransplanted and replaced. Our studies indicate that the agarose-collagen/Gelfoam macrobeads we have developed serve both to protect islet xenografts from rejection and to provide a microenvironment in which the islets maintain and support their normal function in vivo. Because they may be retrieved after implantation and replaced, these macrobeads may be suitable for human clinical islet cell xenotransplantation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7871558

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Retrieval of Microencapsulated Islet Grafts for Post-transplant Evaluation.

Authors:  John Patrick McQuilling; Sivanandane Sittadjody; Rajesh Pareta; Samuel Pendergraft; Clancy J Clark; Alan C Farney; Emmanuel C Opara
Journal:  Methods Mol Biol       Date:  2017

Review 2.  Stem cell microencapsulation for phenotypic control, bioprocessing, and transplantation.

Authors:  Jenna L Wilson; Todd C McDevitt
Journal:  Biotechnol Bioeng       Date:  2013-01-17       Impact factor: 4.530

Review 3.  Engineering the vasculature for islet transplantation.

Authors:  Daniel T Bowers; Wei Song; Long-Hai Wang; Minglin Ma
Journal:  Acta Biomater       Date:  2019-05-23       Impact factor: 8.947

Review 4.  Regenerative medicine as applied to general surgery.

Authors:  Giuseppe Orlando; Kathryn J Wood; Paolo De Coppi; Pedro M Baptista; Kyle W Binder; Khalil N Bitar; Christopher Breuer; Luke Burnett; George Christ; Alan Farney; Marina Figliuzzi; James H Holmes; Kenneth Koch; Paolo Macchiarini; Sayed-Hadi Mirmalek Sani; Emmanuel Opara; Andrea Remuzzi; Jeffrey Rogers; Justin M Saul; Dror Seliktar; Keren Shapira-Schweitzer; Tom Smith; Daniel Solomon; Mark Van Dyke; James J Yoo; Yuanyuan Zhang; Anthony Atala; Robert J Stratta; Shay Soker
Journal:  Ann Surg       Date:  2012-05       Impact factor: 12.969

Review 5.  Type 1 diabetes and engineering enhanced islet transplantation.

Authors:  Abiramy Jeyagaran; Chuan-En Lu; Aline Zbinden; Andreas L Birkenfeld; Sara Y Brucker; Shannon L Layland
Journal:  Adv Drug Deliv Rev       Date:  2022-08-21       Impact factor: 17.873

Review 6.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

Review 7.  Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells.

Authors:  Mohammed I Khan; Anna M Czarnecka; Igor Helbrecht; Ewa Bartnik; Fei Lian; Cezary Szczylik
Journal:  Stem Cell Res Ther       Date:  2015-09-16       Impact factor: 6.832

8.  MEF2 plays a significant role in the tumor inhibitory mechanism of encapsulated RENCA cells via EGF receptor signaling in target tumor cells.

Authors:  Prithy C Martis; Atira T Dudley; Melissa A Bemrose; Hunter L Gazda; Barry H Smith; Lawrence S Gazda
Journal:  BMC Cancer       Date:  2018-12-04       Impact factor: 4.430

9.  A comprehensive microbiological safety approach for agarose encapsulated porcine islets intended for clinical trials.

Authors:  Lawrence S Gazda; James Collins; Archie Lovatt; Robert W Holdcraft; Merribeth J Morin; Daniel Galbraith; Melanie Graham; Melissa A Laramore; Christine Maclean; John Black; Euan W Milne; Douglas G Marthaler; Horatiu V Vinerean; Michelle M Michalak; Deborah Hoffer; Steven Richter; Richard D Hall; Barry H Smith
Journal:  Xenotransplantation       Date:  2016-11-11       Impact factor: 3.907

10.  First-in-Human Phase 1 Trial of Agarose Beads Containing Murine RENCA Cells in Advanced Solid Tumors.

Authors:  Barry H Smith; Tapan Parikh; Zoe P Andrada; Thomas J Fahey; Nathaniel Berman; Madeline Wiles; Angelica Nazarian; Joanne Thomas; Anna Arreglado; Eugene Akahoho; David J Wolf; Daniel M Levine; Thomas S Parker; Lawrence S Gazda; Allyson J Ocean
Journal:  Cancer Growth Metastasis       Date:  2016-08-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.